HR | 95% CI | p-Value | |
---|---|---|---|
Treatment | |||
Pirfenidone | 1.00 | – | – |
Nintedanib | 1.80 | 1.25–2.60 | < 0.01 |
Age at treatment initiation | 1.03 | 1.01–1.06 | 0.02 |
Sex | |||
Male | 1.00 | – | – |
Female | 0.65 | 0.42–1.02 | 0.06 |
Year of antifibrotic treatment initiation | |||
2015 | 1.00 | – | – |
2016 | 0.62 | 0.42–0.91 | 0.01 |
Time from IPF diagnosis to treatment initiation | 1.00 | 0.99–1.01 | 0.51 |
Number of acute respiratory-related hospital admissions during the year prior to treatment initiation | |||
0 | 1.00 | – | – |
1 | 1.29 | 0.89–1.85 | 0.18 |
2 or more | 1.70 | 1.09–2.64 | 0.02 |
Number of outpatient visits to a hospital physician during the year prior to treatment initiation | |||
0 | 1.00 | – | – |
1 or 2 | 1.22 | 0.59–2.50 | 0.59 |
3 or 4 | 1.19 | 0.56–2.53 | 0.65 |
5 or more | 1.85 | 0.90–3.79 | 0.09 |
Charlson comorbidity score | |||
1–2 | 1.00 | – | – |
3–4 | 1.57 | 0.79–3.13 | 0.19 |
5 or more | 2.48 | 1.19–5.16 | 0.02 |
Use of supplemental oxygen at baseline | |||
Yes | 3.27 | 2.34–4.58 | < 0.01 |